CSJA Stock Overview
Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
CSL Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$85.50 |
| 52 Week High | AU$95.00 |
| 52 Week Low | AU$78.00 |
| Beta | 0.30 |
| 11 Month Change | -3.39% |
| 3 Month Change | -7.07% |
| 1 Year Change | 8.92% |
| 33 Year Change | -11.86% |
| 5 Year Change | 0.59% |
| Change since IPO | 243.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| CSJA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.3% | -1.1% | 1.1% |
| 1Y | 8.9% | -18.8% | 7.2% |
Return vs Industry: CSJA exceeded the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: CSJA matched the German Market which returned 8.6% over the past year.
Price Volatility
| CSJA volatility | |
|---|---|
| CSJA Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CSJA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: CSJA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1916 | 32,698 | Paul McKenzie | www.csl.com.au |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
CSL Limited Fundamentals Summary
| CSJA fundamental statistics | |
|---|---|
| Market cap | €83.61b |
| Earnings (TTM) | €2.50b |
| Revenue (TTM) | €14.01b |
33.4x
P/E Ratio6.0x
P/S RatioIs CSJA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSJA income statement (TTM) | |
|---|---|
| Revenue | US$14.80b |
| Cost of Revenue | US$7.10b |
| Gross Profit | US$7.71b |
| Other Expenses | US$5.06b |
| Earnings | US$2.64b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | 5.46 |
| Gross Margin | 52.06% |
| Net Profit Margin | 17.85% |
| Debt/Equity Ratio | 54.2% |
How did CSJA perform over the long term?
See historical performance and comparison